Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York
dc.contributor.author | Girardin, Jean-Louis | |
dc.contributor.author | Seixas, Azizi | |
dc.contributor.author | Ramos Cejudo, Jaime | |
dc.contributor.author | Osorio, Ricardo S | |
dc.contributor.author | Avirappattu, George | |
dc.contributor.author | Reid, Marvin | |
dc.contributor.author | Parthasarathy, Sairam | |
dc.date.accessioned | 2021-03-18T21:21:27Z | |
dc.date.available | 2021-03-18T21:21:27Z | |
dc.date.issued | 2021-02-08 | |
dc.identifier.citation | Girardin, J. L., Seixas, A., Ramos Cejudo, J., Osorio, R. S., Avirappattu, G., Reid, M., & Parthasarathy, S. (2021). Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York. Chronic Respiratory Disease, 18, 1479973120986806. | en_US |
dc.identifier.issn | 1479-9723 | |
dc.identifier.pmid | 33550849 | |
dc.identifier.doi | 10.1177/1479973120986806 | |
dc.identifier.uri | http://hdl.handle.net/10150/657106 | |
dc.description.abstract | We examined the relative contribution of pulmonary diseases (chronic obstructive pulmonary disease, asthma and sleep apnea) to mortality risks associated with Coronavirus Disease (COVID-19) independent of other medical conditions, health risks, and sociodemographic factors. Data were derived from a large US-based case series of patients with COVID-19, captured from a quaternary academic health network covering New York City and Long Island. From March 2 to May 24, 2020, 11,512 patients who were hospitalized were tested for COVID-19, with 4,446 (38.62%) receiving a positive diagnosis for COVID-19. Among those who tested positive, 959 (21.57%) died of COVID-19-related complications at the hospital. Multivariate-adjusted Cox proportional hazards modeling showed mortality risks were strongly associated with greater age (HR = 1.05; 95% CI: 1.04–1.05), ethnic minority (Asians, Non-Hispanic blacks, and Hispanics) (HR = 1.26; 95% CI, 1.10–1.44), low household income (HR = 1.29; 95% CI: 1.11, 1.49), and male sex (HR = 0.85; 95% CI: 0.74, 0.97). Higher mortality risks were also associated with a history of COPD (HR = 1.27; 95% CI: 1.02–1.58), obesity (HR = 1.19; 95% CI: 1.04–1.37), and peripheral artery disease (HR = 1.33; 95% CI: 1.05–1.69). Findings indicate patients with COPD had the highest odds of COVID-19 mortality compared with patients with pre-existing metabolic conditions, such as obesity, diabetes and hypertension. Sociodemographic factors including increased age, male sex, low household income, ethnic minority status were also independently associated with greater mortality risks. | en_US |
dc.language.iso | en | en_US |
dc.publisher | SAGE Publications Ltd | en_US |
dc.rights | © The Author(s) 2021. Article reuse guidelines: sagepub.com/journals-permissions. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/). | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en_US |
dc.subject | COPD | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Ethnic Minority | en_US |
dc.subject | metabolic | en_US |
dc.subject | Mortality | en_US |
dc.subject | sociodemographic | en_US |
dc.title | Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1479-9731 | |
dc.contributor.department | Division of Pulmonary, Allergy, Critical, Care and Sleep Medicine, University of Arizona | en_US |
dc.identifier.journal | Chronic Respiratory Disease | en_US |
dc.description.note | Open access journal | en_US |
dc.description.collectioninformation | This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu. | en_US |
dc.eprint.version | Final published version | en_US |
dc.source.journaltitle | Chronic respiratory disease | |
dc.source.volume | 18 | |
dc.source.beginpage | 1479973120986806 | |
dc.source.endpage | ||
refterms.dateFOA | 2021-03-18T21:21:37Z | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | England |